Trial reportBMC endocrine disorders2026
The role of short-term metformin in regulating zinc and adipose tissue-derived biomarkers in children with obesity and insulin resistance.
Trial report in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT06266598. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Anti-diabetic Treatment Applied in Childhood Obesity on Zinc, Zinc α-2 Glycoprotein and Peroxisome Proliferation Activating Receptor-γ Levels
Open the trial in the graphWho cites it
1 citing paper in PubMed.
- The Association Between Serum Zinc Levels, Conventional and Novel Anthropometric Indices in Postmenopausal Women in Montenegro - a Cross-Sectional Study.Biological trace element research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimTo evaluate the short-term effects of metformin treatment on serum zinc (Zn), zinc-α2-glycoprotein (ZAG), peroxisome proliferator-activated receptor gamma (PPARγ), leptin (LEP), and adiponectin (ADIPO) levels in obese and insulin-resistant children compared with healthy controls.
methodsFifty-two children with obesity and insulin resistance (IR) and 33 age-matched healthy controls were included. The patient group received metformin for three months alongside lifestyle advice. Anthropometric data and the serum levels of Zn, ZAG, PPARγ, LEP, and ADIPO were measured before and after treatment. The outcomes were also analyzed on the basis of weight change.
resultsAt baseline, the obesity group presented lower ZAG and ADIPO and higher LEP and IR indices than the control group did (p < 0.001). After treatment, BMI, insulin, HOMA-IR, and HDL-C improved. The serum Zn, ZAG, ADIPO, and LEP levels increased significantly (p < 0.05), whereas the PPARγ level remained unchanged. Although 73% had lost weight, 27% had gained weight. In the weight-gain group, both LEP and ADIPO increased, suggesting a weight-independent adipokine response to metformin.
conclusionMetformin led to short-term improvements in metabolic and adipokine profiles in children with obesity and IR. The increase in ADIPO, even among those who gained weight, may reflect the potential weight-independent effect of metformin on insulin sensitivity. CLINICAL
trial registrationClinicalTrials.gov, NCT06266598. Registration date: February 11, 2024.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.